A news scan found the notes of an automated trading fund manager. The manager trained a model called QIM90708 on the EEM stock from 2016 to 2020 and tested it from 2021 to 2025 and recently up to September 4, 2026. The model only used full New York Stock Exchange sessions and was calibrated with a tool called exchange_calendars version 4.13.2. The model also used adjusted stock bar data from a website. The manager applied a 5 basis point fee and 5 basis point lippage, which is a type of trading cost, to each trade. The model only made long trades, meaning it only bought stocks, and used all available capital. The results showed a return of -72.392945 percent and a maximum drawdown of 72.392945 percent. The model had 664 trades, with a win rate of 11.144578 percent. The average win was 0.162341 percent and the average loss was 0.238069 percent. These results are simulated and do not reflect actual account performance. The model did not use same-day stop or target orders and did not guarantee auction-fill orders. The manager concluded that this model should be rejected due to its high costs. The manager tested six different cost variants, but changing the costs did not improve the results. The original research papers for this model can be found at https://smallake.kr/wp-content/uploads/2015/01/SSRN-id2440866.pdf and https://academicweb.nd.edu/~zda/intramom.pdf. This model is a long-only transfer of an ETF, not a full replication of a research paper. The historical market period used to test the model is not a pristine prospective validation, meaning it is not a perfect test of the model's performance.
The QIM90708 SPY recent costed final-half-hour cash-only replication analysis is based on frozen notes 651 and 653. The entry point was at 15:30 bar open, with an exit at the close of that 30-minute bar, resulting in a flat position on the same day. The analysis was trained on data from 2016 to 2020, with a holdout period from 2021 to 2025, and recent data up to September 4, 2026. Only full New York Stock Exchange sessions were considered, calibrated with exchange calendars version 4.13.2 and adjusted SIP bars from https://runway.adityaperswal.workers.dev/data/stock-bars. A 5 basis point fee and 5 basis point slippage were applied to each side of the trade. The vectorbt direction was set to long only, with all available strategy capital and cash reconciled independently. The results showed a return of -16.249382%, with a closed wealth drawdown of 16.249382%, 93 trades, a win rate of 8.602151%, a mean return of -0.190383%, an average win of 0.129372%, and an average loss of 0.220477%. These simulated full-capital returns do not reflect actual account performance. The analysis did not include same-day stop or target orders, or auction-fill guarantees, and excluded intrabar drawdowns. The conclusion is to reject this costed transfer, with an actual size of 0. All six cost variants were recorded, but changing costs did not select a winner. The original sources are https://smallake.kr/wp-content/uploads/2015/01/SSRN-id2440866.pdf and https://academicweb.nd.edu/~zda/intramom.pdf, and this analysis is an ETF long-only transfer, not a full paper replication. The inspected historical market period is not a pristine prospective validation.
A news scan found the following text: 1. Frozen notes 651/653, with a positive result; the earliest signal allowed by a maximum of 3 trades per rolling 5 sessions, entry at 15:30 bar open, exit at that 30-minute bar close; the position was closed the same day. The training period was from 2016 to 2020, the holdout period was from 2021 to 2025, and the recent period was from 2026 through September 4. Only full New York Stock Exchange sessions were used, calibrated with exchange calendars version 4.13.2; adjusted SIP bars can be found at https://runway.adityaperswal.workers.dev/data/stock-bars. 2. A 5 basis point fee and 5 basis point slippage were applied to each side of the trade; the vectorbt direction was long only, using all available strategy capital, with cash reconciled independently. The return was -71.726262%, the closed wealth drawdown was 71.726262%, with 569 trades, a win rate of 13.532513%, a mean return of -0.221451%, an average win of 0.168343%, and an average loss of 0.282455%. These are simulated full-capital returns, not actual account performance. 3. There was no same-day stop or target, and no auction-fill guarantee; intrabar drawdown was excluded. The PDT throttle is per isolated ETF, not a combined account allocation. The conclusion is to reject this costed transfer, with an actual size of 0. All six cost variants were recorded, but changing costs did not select a winner. The original sources are https://smallake.kr/wp-content/uploads/2015/01/SSRN-id2440866.pdf and https://academicweb.nd.edu/~zda/intramom.pdf; this is an ETF long-only transfer, not a full paper replication. The inspected historical market period is not pristine prospective validation.
This is a report on a trading strategy test. The test used historical data from 2016 to 2020 to train the strategy and data from 2021 to 2025, and up to September 4, 2026, to test it. The test only used full trading days on the New York Stock Exchange and adjusted for certain market factors. The strategy was tested with a 5 basis point fee and 5 basis point slippage on each trade, which means a small cost was added to each buy and sell order. The test results showed a return of -75.849062%, which means the strategy lost value, and the largest loss from peak to trough was also -75.849062%. The strategy had 674 trades, with 13.798220% of them being winners, and the average win was 0.136409%, while the average loss was 0.265807%. These results are based on simulated trades, not actual account performance. The test did not guarantee that trades would be filled at certain prices or that stops and targets would be executed on the same day. The test also did not account for potential losses within a trading period. The conclusion is to reject this strategy due to its poor performance. The test was based on two research papers, but it is not a full replication of the papers' findings, and the historical data used may not be a perfect representation of future market conditions.
A news scan found the report of an automated trading fund manager. The report is about a costed final-half-hour cash-only replication of the SPY, which is a type of exchange-traded fund. The manager used frozen notes from 651 to 653, and the entry point was at 15:30 when the price was higher than the previous day's close. The manager exited at the close of the same 30-minute bar and was flat by the end of the day. The training period was from 2016 to 2020, the holdout period was from 2021 to 2025, and the recent period was from 2026 to September 4. The manager only used full New York Stock Exchange sessions and calibrated the data with exchange calendars version 4.13.2. The manager also adjusted the bars using a specific website. The manager paid 5 basis points in fees and 5 basis points in slippage on each side of the trade. The manager used a long-only strategy with all available capital and reconciled the cash independently. The return was -77.777294%, the closed wealth drawdown was 77.777294%, and there were 704 trades. The win rate was 13.778409%, the mean return was -0.213134%, the average win was 0.147373%, and the average loss was 0.270744%. These results are simulated and not based on actual account performance. The manager did not use same-day stop or target orders and did not guarantee auction fills. The manager also excluded intrabar drawdowns from the results. The conclusion is to reject this costed transfer with an actual size of 0. The manager recorded all six cost variants but found that changing costs did not select a winner. The original sources of the information are two academic papers, and this is an ETF long-only transfer, not a full paper replication. The historical market period inspected is not a pristine prospective validation.
A news scan found a report about a trading strategy test. The test used historical data from 2016 to 2026 to see how well a strategy would work. The strategy was tested on the SPY stock, which is a type of investment fund, and it only considered buying, not selling. The test included costs of 5 basis points, which is a measure of the cost of a trade, and 5 basis points of slippage, which is the difference between the expected price and the actual price. The results showed a return of -73.724632%, which means the strategy lost value. The strategy had 12% winning trades, with an average win of 0.283811% and an average loss of 0.254857%. The test did not guarantee that trades would be filled at a certain price or that losses would be limited. The conclusion was to reject this strategy. The test was based on research papers from academic sources, but it is not a perfect test of the strategy's potential performance.
A news scan found the report of an automated trading fund manager. The manager tested a trading strategy on the SPY stock, which is an exchange-traded fund, or ETF, that tracks the S&P 500 index. The test used data from 2016 to 2020 to train the strategy and data from 2021 to 2025 as a holdout period, and also included recent data up to September 4, 2026. The test only used full New York Stock Exchange sessions and was calibrated with a specific calendar version, 4.13.2, and adjusted for certain stock bar data found at https://runway.adityaperswal.workers.dev/data/stock-bars. The strategy had fees of 5 basis points, or 0.05%, and slippage of 5 basis points on each side of a trade, meaning the strategy paid a small cost to buy and sell stocks. The strategy was set to only buy stocks, not sell them short, and used all available capital. The test results showed a return of -75.820904%, a closed wealth drawdown of 75.820904%, 684 trades, a win rate of 11.111111%, a mean return of -0.206817%, an average win of 0.271463%, and an average loss of 0.266602%. These results are simulated and do not reflect actual account performance. The test did not guarantee that trades would be filled at a certain price or that stops and targets would be executed on the same day. The test also did not include drawdown that occurred within a single bar, or period, of trading. The conclusion was to reject this strategy due to its poor performance, with no trades actually being made, or a size of 0. Six different cost variants were tested, but changing the costs did not improve the results. The original sources of the strategy were found in two research papers at https://smallake.kr/wp-content/uploads/2015/01/SSRN-id2440866.pdf and https://academicweb.nd.edu/~zda/intramom.pdf. This test was a transfer of a strategy to an ETF, not a full replication of a research paper, and the historical market period used was not a pristine, or perfect, test of the strategy's potential future performance.
The start state is 49.14 in Catalyst cash and 850.99 in account equity, with no open or queued positions. The goal is to achieve a repeatable net pre-event gain. There are several premises to consider. Firstly, a new ROI notice from Roivant on September 6 mentions PHocus ERS, which will be discussed on September 8 at 06:15 ET, before the 08:00 ET call and 09:30 ET open. Secondly, a frozen ROI generic SMA 10/50 costed holdout has shown a 187.00% return over three months, with no observed losses, but this cannot be used to calibrate a clinical runup. Thirdly, an existing CHWY fixed 10-session holdout analysis has shown a return of -1.720%, with a drawdown of 14.259%, and shortening this to one remaining day is untested. An existing GIS analysis has also been rejected. A live Catalyst ledger query has shown 0 wins out of 3 trades, with a mean loss of 16.3806%. The new ROI risk context has a support target of 1.146, with a 30% gap of 10.4835, which is greater than the risk budget of 8.5099. The conclusion is to not propose, exit, adjust, or fund, and to adopt a size of quarter Kelly 0. The validity of this decision is limited by the lack of evidence and the use of partial IEX data. A strong countercase is that good data could lead to a rally and a long-term payoff, but this does not establish a current runup entry. The decision will only be changed with a verified event, an unexpired tested window, independent net edge, executable quotes, and a realistic risk-reward ratio of at least 1.5. Favorable results will lead to prospective research, while weak or ambiguous results will lead to cash preservation. Monthly shortfall is not a model input. The calendar analysis covers the next two sessions, and 20 existing monitors have been retained, with the ROIV addition rejected. No Catalyst monitor is currently due, and other funds' issues will not be resolved. The archive notes have been read back, and no live holding needs to be stopped.
A five-session simulation of ROIV, using 100,000 paths sampled from 752 daily returns from 2022 to 2024, was conducted with a Numpy seed of 9070800. The mean gross endpoint return was +0.46984%, with a 5th percentile of -12.52714% and a 95th percentile of +14.86795%, and a loss of 49.822%. These results represent generic daily risk, not forecasts of clinical outcomes. The simulation used a descriptive sensitivity analysis with an ATR of 1.1575 and a price of 34.945 to set a stop loss at 3.312% and a target at 4.969%. The simulation also included daily endpoint checks, with a stop loss and target cap, and a fee of 5 basis points and a slip of 10 basis points on each side. The base net mean return was -1.02070%, with a win rate of 45.992%, a stop loss rate of 44.685%, and a target rate of 33.972%, with an average time of 21.343%. The one-share 5th percentile loss was $3.272. The simulation also assumed extra gap probabilities of 1%, 5%, and 10% on the first day, which produced mean returns of -1.29903%, -2.49798%, and -3.96143%, respectively, with one-share loss odds of 9.424%, 4.949%, and 9.894%, respectively. The results showed zero exceedances in the zero added-gap scenario, but this is a finite empirical model result and does not represent zero real tail risk. The overlay probabilities were not estimated, and the IID assumption destroys clustering, while daily checks miss 15-minute and extra-hours paths, and the historical pool already contains news, which may double-count added gaps. The positive unconstrained endpoint mean does not validate a profit-taking strategy. In conclusion, the simulation size was 0, and neither the Monte Carlo simulation of 100,000 nor a generic 3-win holdout supplies independent clinical edge or calibrated Kelly. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars, and the scripts roiv.py and simulation.py are archived. The model will be frozen prospectively rather than retuning barriers.
The PHocus study is a randomized trial with 135 patients in Phase 2, looking at primary results at week 16, including PVR and 6MWT, and secondary results, including NTproBNP. The study is sponsored by a company that uses a once-daily inhaled sGC, which is a type of enzyme, and is also doing a separate study with inhaled treprostinil, a type of medication. The results of the IONS study on September 4 provide an example that shows biomarkers, which are indicators of a biological process, do not always translate to clinical results, and do not provide evidence that these mechanisms work in the same way. There are three possible outcomes: first, if the study shows a clear benefit with acceptable safety, it could justify further development; if the data is weak or unclear, it may not. Second, if the study shows a sustained functional benefit and is well-tolerated, it could affect how patients are recruited for trials, how doctors prescribe the treatment, and how much payers are willing to pay; if the benefits are only seen in certain groups or if there is missing data, it may not have as much of an impact. Third, only after the treatment is approved and is being used profitably might the economics of the treatment affect the companies involved, including Roivant and UTHR; just because one company has a successful treatment does not mean the other company will automatically be affected. The development of combination treatments means that a rival treatment does not have to be a direct substitute. The people who may benefit from this study are patients if the outcomes are improved, trial providers if there are further studies, and shareholders if the development costs, ownership, and reimbursement are favorable. The strongest positive case is if the treatment is differentiated and well-funded, and the strongest negative case is if there are gaps in the data or safety concerns and the market pricing can absorb good data. In conclusion, it is necessary to monitor the full data, and the probabilities and margins of the commercial outcomes remain unmeasured.
A test was run on the ROIV symbol using a simple moving average cross strategy. The test used 10 and 50 as the fast and slow moving average parameters and considered 1700 days of data. The results showed 1167 bars, 13 closed trades, a return of 232.87%, a maximum drawdown of 50.69%, a win rate of 38.46%, and an average trade return of 14.08%. For comparison, a buy and hold approach would have returned 336.27%. The test assumed same-close signal and fill, with no costs or independent split, using data from https://runway.adityaperswal.workers.dev/data/stock-bars. This test was for diagnostic purposes only and did not calibrate for actual events. A separate experiment using vectorbt with next-open and including holdout and fees/slippage was also conducted. The results of this test should not be confused with the vectorbt test that started on January 3, 2022, or the best gross result. The verdict from this test was not adopted and the allocation was set to 0.
A preregistered note, numbered 652, was made before the analysis. The analysis used a system called vectorbt, which relies on the previous day's closing price to decide when to enter or exit a trade, with the actual trade happening at the next day's opening on the IEX exchange, including fees of 5 basis points and slippage of 10 basis points for each buy or sell. The analysis was divided into two periods: a training period from 2022 to 2024, and a holdout period from 2025 to September 4, 2026. The baseline strategy, which used two moving averages with periods of 10 and 50 days, resulted in a gain of 10.0652% during the training period, with a maximum drawdown of 52.0737%, and 3 out of 11 trades were winners, with an average win of 34.8752% and an average loss of 8.1652%. In the holdout period, the strategy gained 186.9989%, with a maximum drawdown of 12.8047%, and all 3 trades were winners, with an average win of 52.4166% and no losses observed. The trades in the holdout period were made on April 29 to July 14, 2025, with a gain of 2.1572%, July 15, 2025, to May 4, 2026, with a gain of 136.0114%, and May 13 to September 4, 2026, with a gain of 19.0810%. These trades were held for months, not just a few sessions. When slippage of 25 basis points was included, the holdout period gain was 184.4275% and the training period gain was 6.4923%. Another strategy, with faster moving averages of 5 and 20 days, was also tested, with results of -33.5916% and +48.8584% in the training period, and +107.5309% and +203.3550% in the holdout period, but no winning variant was selected. The conclusions drawn from this analysis are based on a positive record for the selected issuer, a small holdout period with no observed losses, and no filters based on the calendar or validated stops and targets. However, the strategy is rejected for use in sizing catalysts and there is no proposal for a fund due to the lack of independent validation. The trend is robust to costs, but the return should be accepted with caution and not used to infer success in future events or new entries. This holdout period cannot be reused to adjust the strategy. The data source is https://runway.adityaperswal.workers.dev/data/stock-bars, and the code used is in research/backtest.py and trade vectors, with observations numbered 8988 to 8999. Both return and drawdown are expressed as percentages, and having three wins does not mean the probability of success is 1.
A news scan found the headline 'ROIV trend-state conflict: crossover state versus recent price weakness'. The source is a data line from Sep 4 IEX https://runway.adityaperswal.workers.dev/data/stock-bars. It shows the Simple Moving Average, or SMA, which is a way to smooth out price changes, for 10, 20, and 50 days were 35.454, 35.91775, and 35.2768. The close price was 34.945, which is below all three, and the return over 20 sessions was -3.77255%. However, the 10-day SMA is still greater than the 50-day SMA. This is called a lagging positive crossover state, which is not a fresh entry signal, and recent price weakness does not prove failure. A frozen SMA 10/50 generic backtest had its last entry on May 13, not Sep 7, and there is no mandate-compatible pre-event session left. The premises indicators mix different lookbacks, so there is no optimistic pick-one interpretation. A counterargument is that the long trend may resume, and it is possible to accept this possibility without converting it into a probability of success. There will be no new subgroup search or fit on now seen holdout, and the allocation is 0.
On September 4, the IEX bar closed at 34.945. The simple Average True Range, or ATR, over 14 days was 1.1575, and the Average Daily Range, or ADR, over 14 days was 1.12. The 20-day low and high were 33.43 and 37.92, respectively, with a 20-day return of -3.77255% and an annualized 20-day volatility of 35.02595%. The mean IEX volume was 350,422.75. This data comes from a source at https://runway.adityaperswal.workers.dev/data/stock-bars, based on observations 8981, 8985, and 8987. One share of ROIV costs 34.945 before costs, which is within the 49.14 fund cap. An illustrative stop at 1 ATR, or 33.7875, and a target at 1.5 ATR, or 36.68125, would yield a nominal 1.5 risk-reward ratio, but this has not been validated by fundamental analysis or orders. A stop at the 20-day low of 33.43 would give only a 1.146 risk-reward ratio with the same target, and stretching to 37.92 is not recommended. A 20% gap loss of 6.989 or a 30% gap loss of 10.4835 would exceed the account budget of 8.5099. A stop is not a guarantee, and even with a whole-share extended hours trade, it is still not possible to bound the gap. Given the premises of an affordable ordinary range, unknown binary tail, and no remaining regular session before September 8 at 06:15 ET, a news release found at https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat, the conclusion is that no order or stop is requested. A positive price context would not repair the missing event edge, and range estimates are partial and based on historical, non-executable quotes.
A preregistered note, number 652, analyzed the daily return of ROIV using a linear regression model, also known as ordinary least squares or OLS, where daily ROIV return equals a plus b times SPY return, using all-adjusted IEX bars from January 3, 2022, through September 4, 2026, available at https://runway.adityaperswal.workers.dev/data/stock-bars. The analysis was divided into two periods: a training period from 2022 to 2024 with 752 paired returns, which had a beta of 1.09843, a correlation of 0.32355, an R-squared of 0.10468, and an intercept of 0.04914% per day, and a holdout period from 2025 to September 4, 2026, with 420 paired returns, which had a beta of 0.91825, a correlation of 0.39021, an R-squared of 0.15226, and an intercept of 0.21894% per day. The mean and standard deviation of daily ROIV returns were 0.09205% and 3.73385% for the training period, and 0.28739% and 2.46271% for the holdout period. The premises of the analysis were that the low R-squared and large idiosyncratic dispersion, which refers to the variation in returns that is specific to individual stocks, indicate that the model does not explain much of the daily variance in ROIV returns, and that clinical events, which are significant events that affect a stock's price, are specific to the ticker, or stock symbol. The conclusion is that macroeconomic trends, or macro prints, describe the context, but do not predict the likelihood or forecast of alpha, which refers to the excess return of a stock over the market average. The intercepts are descriptive fits within each partition, but not forecasts or estimates of abnormal returns. A counter case could be that broader risk-on, which refers to a market environment where investors are taking on more risk, could matter, but the beta near 1 supports only some exposure, and only 10-15% of the variance is explained. No statistical significance or regime stability is claimed. The analysis is limited by survivorship bias, which refers to the bias that occurs when only surviving companies are included in the analysis, news contamination, which refers to the impact of news events on stock prices, partial IEX, which refers to the use of only some of the data available from the IEX exchange, and adjustment revisions, which refer to changes made to the data after it was initially released. The analysis requires prospective event data, rather than repeated queries that create false independence, and allocation is 0.
The Roivant company has announced some updates. First, on September 6, the company fixed the date for releasing the results of a study called PHocus on September 8 at 6:15 ET, and they will have an investor call at 8 ET. The study is about a treatment called mosliciguat. The company's website has more information about this. The study has 135 participants and is looking at how well the treatment works. The company said in February that there were about 120 participants, but the actual number is higher. The study was supposed to be finished in December, but now it will be presented in September. We need to verify when the study actually ended and if it is complete. Second, the company's financial report from August 6 shows that they had $3.842 billion in cash and securities on June 30. They spent $270.504 million in the quarter, which is 32.35% more than the same time last year. They also spent $83.342 million on stock-based compensation and $206.729 million on repurchasing shares. The company's burn rate is $1.082 billion per year, and they have enough cash to last 14.20 quarters. However, this is just an estimate and not a forecast. The company also received $771.6 million from Genevant on July 8, which is separate from their cash on June 30. Pulmovant, a company owned by Roivant, has 97% basic ownership and 90% fully diluted ownership. The value of Roivant's shares on July 31 was $25.242 billion, and their cash per share was $5.319, which is 15.22% of the total value. Fourth, the company's treatment called brepocitinib was approved on August 27. In conclusion, the PHocus study results will be presented soon, but the company's strong cash position and the mechanism of the treatment do not necessarily mean it will be successful. The success of the treatment depends on many factors, including its effectiveness, commercial economics, and reimbursement model. The facts are based on the company's filings and study design, but the probability of success is not estimated.
The New York Stock Exchange website confirms that the stock market was closed on September 7 and the next two stock sessions will be on September 8 and 9. There are no current quant positions, pending orders, or due monitors. A review of held positions, targets, and horizons is not applicable. Other fund due monitors are not quant positions or delegated tasks. The following issuer events are scheduled: INBX will have a clinical call on September 8 at 8 ET, BRZE and CASY will release earnings after the close on September 8, GME will release full results on a date following a pre-announcement, CHWY and ASO will release earnings before the open on September 9, TYRA and IRD will have clinical calls on September 9 at 8 ET, and Inditex will release results on September 9. Existing monitors 46, 47, and 48, and clinical job 35 remain active. New quant monitors 59 and 60 have been added. The economic calendar includes the Census QF on September 8 at 10 ET, the NY Fed SCE on September 8 at 11 ET, and the Fed credit on September 8 at 15 ET. On September 9, the ECEC and QSS will be released at 10 ET. A search of FDA meetings found policy and town hall meetings, but no newly confirmed PDUFA on September 8 or 9. The TLX deadline is September 11, with the possibility of an early decision. There are no pre-open orders or stops, and the edge is unvalidated. The strategy is to record complete prospective evidence and test independent net payoff for favorable events, and to record equally and stay cash for adverse or ambiguous events. Changes will only be made with positive training, holdout, cost stress, uncertainty above zero, executable actual management, fresh signal, and sizing within 21.27475 position, 8.5099 nominal risk, and 245.69 fund cash. News, gaps, or monthly shortfalls alone cannot satisfy these conditions. Primary URLs are recorded in observations 8930-8944.
A news scan found the report that the QIM90708 own-record calibration resulted in three liquidations with returns of -5.392364%, +7.939941%, and -5.130499%. The average win was 7.939941% and the average loss was 5.261432%, with a mean of -0.860974% and a realized loss of $1.046053. This is based on a first-party query of trades from the quant fund on September 7, with exact arithmetic saved in research/ledger.json. The report notes that all three exits were operator liquidations, not planned stop or target exits, and that entry orders were market orders without reference quotes, making it impossible to compare slippage. The report concludes that the results should not be transferred to intraday momentum or claimed as a PEAD win probability, despite DELL's 7.94% gain, as one selected winner cannot identify the intended payoff.
A news scan found the headline about GameStop's preliminary results. On August 31, the company announced preliminary sales of $780-800 million and operating income of $150-170 million. This implies a revenue decline of 18.741% and an operating margin of 20.253%, compared to 6.830% in the prior year. However, store closures make it hard to compare the numbers. The company also reported a gain of $163 million from its investment in eBay, which is 54.333% of its midpoint net income of $300 million. The company's cash and securities decreased by 41.799% to $5060 million, partly due to its investment in eBay. On September 8, the company will release its complete results, which should be compared to the preliminary ranges announced on August 31. A higher EPS headline alone will not be a surprise. The strongest counterargument is that the operating margin improvement could be lasting. The company's fair equity value cannot be determined without considering debt and dilution. The source of this information is the GameStop investor website.
A news scan found the event calendar for September 8-9. The calendar includes observations from 8954 to 8975 with individual source URLs and claim dates. The premises are as follows: 1. The New York Stock Exchange, or NYSE, which is a stock exchange, closes on September 7 and opens on September 8 at 09:30 ET. 2. On September 8, ROIV has an ERS, or earnings report, at 06:15 ET, which is before the 08:00 ET call, and INBX has an 08:00 ET call, and ABM and UNFI have morning calls, all before the market opens. There are no regular-session entry or exit windows for these events. 3. On September 8 after the market closes, BRZE, CASY, and AVO, and on September 9 before the market opens, CHWY and ASO, and on September 9, TYRA and IRD have 08:00 ET calls, and ITX.MC has a date-only event, providing at most one remaining US session, but none of these events have a tested multi-session run-up. 4. GME pre-announced on August 31, and confirmation is not unanticipated information. The conclusion is to retain a research-only calendar and have zero pre-open orders. A strong counterargument is that extended-hour run-ups or one-session trades could work, but there is no costed evidence to estimate the edge, and the earliest news is uncertain. The inference is valid under the mandate's evidence requirement, but the soundness is limited by the selected universe and incomplete FDA dynamically populated calendar, which is not proof that no other events exist. Macro events include the Census QFR at 10:00 ET on September 8, the NY Fed SCE at 11:00 ET on September 8, and the Fed credit at 15:00 ET on September 8, and on September 9, the BLS June EC and Census Q2 QSS at 10:00 ET, and the EIA STEO date-only. PPI/CPI and holiday-delayed petroleum are on September 10 and 11, not September 8 and 9. The calendar can be found at https://www.census.gov/economic-indicators/calendar-listview.html, https://www.newyorkfed.org/research/calendars/i-sep26.html, https://www.federalreserve.gov/newsevents/2026-september.htm, https://www.bls.gov/schedule/2026/09_sched.htm, https://www.eia.gov/outlooks/steo/outlook.php, and https://www.eia.gov/petroleum/supply/weekly/schedule.php. There is no Catalyst monitor due, and other funds' due monitors are outside this book and should not be resolved. A fresh access gap was found for CASY PDF 403, and the issuer index corroborates the prior date. Positive operational or clinical evidence changes the watch status only, and entry also needs new independent net validation, executable quotes, and pre-event exit.
The automated trading fund manager starts with $235.86 in cash and $850.99 in total equity, with no open or pending crypto orders. The goal is to achieve positive repeatable returns before the next session, with a credible independent net edge being the main constraint, not available cash. The manager has done four analyses: analysis 649 found that the recipient still has 3998.49878021 BTC, but the Liquid explorers are stale or divergent and custody restoration is unverified; analysis 655 checked 30 daily and 728 hourly bars per 7 non-stablecoin names and found that the current data is mostly internally consistent, but older provenance and executable depth are unresolved; analysis 659 recomputed the frozen hourly net expectancy, which is -0.6329% for BTC, -0.7069% for ETH, and -0.5734% for SOL per trade; and analysis 658 verified the next two US sessions, which are on September 8 and 9. The manager concludes that there should be no propose, exit, adjust, or fund actions, and cash should be retained. The soundness of this decision is based on the fact that it is not proven that all future crypto edges will fail, only that the current validation gates fail. The strongest counterexample is momentum in LINK, which could continue, or a bridge that could recover before indexed confirmation, but neither supplies an independently calibrated payoff. The manager has set hard maxima of $8.5099 equity risk and $212.7475 position ceilings, which are not targets. The manager will monitor the situation and has accepted collector 49, 50, and 51 after canceling 45 and 46. All three scripts have passed locally, and the final phase is reserved. The manager has recorded analysis, observations, and lessons, and has finished within 8 minutes of the planned 36 minutes, with no overrun. The sources of the data are listed, including https://runway.adityaperswal.workers.dev/data/crypto-bars and https://blockstream.info/api/address/bc1ql4mfu6aundtkksxklfajs2h3t9nzcd6gyqjlte.
The automated trading fund manager made a decision to retain cash at $278.67 on September 7 at 08:00 UTC. The manager proposed no new trades. The live ledger showed two closed operator liquidations and no open or pending ones. The manager's mean win was 2.27871%, with no loss sample. The quarter-Kelly was undefined. The manager also reviewed the FRO frozen N41 mean interval, which was between -0.874362% and 1.958541%, and the negative AA/CENX actual-exit holdouts, which did not qualify. The manager retained prior work on CLI/vectorbt/indicator/simulation and did not claim any new backtest. The source of the data was https://runway.adityaperswal.workers.dev/data/stock-bars. New analyses, numbered 651, 652, 656, and 657, recorded statistics, fundamentals, consequences, and technical gate. On September 8, the manager noted the following events: Census Q2 QFR10 at 10:00 ET, ASPI at 12:30 ET, and NYFedSCE at 11:00 ET. The manager also noted that BRZE and GME were expected to report their Q2 results, but only the dates were verified. On September 9, the manager noted CHWY and ASO before open, Inditex half-year results, June ECEC at 10:00 ET, and Q2 services at 10:00 ET. The manager also noted the weekly oil report at noon ET. A new monitor, QFR 58, was added to review the September 8 QFR release. The manager inspected the 2026 Q2 disclosure change and same-vintage comparisons. The manager retained existing monitors, including 43 ASPI, 49 STEO, and 50 weekly oil. The manager noted that there were no supply monitors due now or before the next holiday review. The manager also noted that the change-mind gates were accepted for profitable ASPI shipments or demonstrated carrier incremental net cash. Delays, dilution, lower shipped volume, or restoration would weaken the scarcity thesis. The manager retained five jobs, numbered 12, 18, 36, 39, and 44. Job 39 was next, scheduled for September 7 at 10:00:56 UTC. The manager noted that approximately 7 minutes were used, and no thread overran. The manager completed records and lessons 239-241. The initial final strategy write exceeded 4000 characters and was rejected, so this compact replacement is the actual saved decision. No trading tools were used.
The QIM90708 trading rule is based on intraday momentum replication. It uses a last-half-hour timing rule with a same-day exit, as defined by GHLZ, which can be found in a research paper at https://smallake.kr/wp-content/uploads/2015/01/SSRN-id2440866.pdf. Robeco-affiliated authors have also studied rest-of-day momentum in a broader futures universe, but they note that their results do not include costs, as seen in their paper at https://academicweb.nd.edu/~zda/intramom.pdf. Our cash account has certain limitations, including only allowing long exposure, a maximum of three day trades per rolling five sessions, and no guaranteed closing-auction execution or automated scheduled time exit. Based on these conditions, we will test long-only ETF transfers under frozen notes 651/653 and reject them if the net economics are not favorable. The original rule is different from previous experiments that used an Average True Range template, which were not successful. The actual order size is currently zero, and the results or implementation of stop, target, or time-exit strategies have not been validated. We have selected four ETFs to test, but they are not a representative sample of the global universe. The historical period from 2021 to 2025 has not been tested under this rule, although the market during this time has been examined by the fund. The current dealer gamma and exact costs are unknown. We will not optimize the strategy based on the inspected holdout period. We start with $245.69 in cash, aiming to achieve a replicable net edge, with the goal of maximizing tradable payoff, rather than minimizing monthly shortfall.
The automated trading fund manager reviewed archived experiments and found no reliable positive edge to size an allocation. The review consisted of three premises. First, backtests from June 2023, specifically on June 6, 2023, at 06:00 UTC, showed the following results for Bitcoin, Ethereum, and Solana: Bitcoin had a price of 29 out of 115, with a win rate of 99.11125444% and a loss rate of 1.180520989%; Ethereum had a price of 12 out of 118, with a win rate of 4.177281755% and a loss rate of 1.259869640%; and Solana had a price of 12 out of 107, with a win rate of 5.200698903% and a loss rate of 1.302715925%. Second, a Python recomputation of the expected value per trade, calculated as the probability of a win times the win rate minus the probability of a loss times the loss rate, resulted in negative estimates of -0.63289%, -0.70694%, and -0.57336% per completed trade. Additionally, the quarter Kelly criterion, which is a formula used to determine the optimal fraction of a portfolio to allocate to a given trade, gave negative estimates, leading to a conclusion of zero eligible allocation. The costed holdout returns were -52.1851%, -58.5744%, and -49.2381%, with drawdowns of 52.2339%, 66.9159%, and 60.9755%, and win rates of 25.2174%, 10.1695%, and 11.2150%. Third, the manager's own ledger showed that trade 10 was a Bitcoin operator liquidation after 47.93 minutes with a price return of -0.08099%, and the intended 3-4 week strategy was censored, with no wins or full strategy exits, and fee and slippage attribution were unavailable. The conclusion was that there was no reliable positive realized or tested edge to size. A counterargument was that daily alternatives have positive 1-2 trade sensitivity results, but this was not enough to adopt them due to the lack of meaningful loss population and hourly failure. Prior simulations, specifically 605 and 606, showed that drift-removed doubled-cost means were approximately -1.2%, but these simulations were scenarios, not independent edge. The soundness of the results was limited by older bar provenance and sparse daily samples, so no universal claim was made that all crypto rules fail. There was no retuning or new CLI test in this refresh because the rule state stayed rejected, and prior CLI and vectorbt experiments were retained rather than double-counted. The sources of the information were internal research 596-598 and 605-606, as well as external sources including https://runway.adityaperswal.workers.dev/data/crypto-bars and https://docs.alpaca.markets/us/docs/crypto-fees, and a query of trades from the fund crypto database.
The issuer pages for IBIT and ETHA still show 1,384,960,000 and 464,560,000 shares, respectively, as of September 4. This does not necessarily mean there have been no changes since then, but there are no newer measurements available. On September 8, financial reports and consumer expectations will be released at 10:00 ET and 11:00 ET, respectively. On September 9, employer compensation and services data will be released at 10:00 ET. The Ethereum developer decision on September 3 set a date of October 6 for Sepolia, but the mainnet timing is not verified. The calendar sets research checkpoints, but not expected returns. An unexpected macro surprise can move crypto prices sharply, but without a calibrated model, the direction and magnitude cannot be predicted. The assumption is that inflation and credit news can change rates and liquidity expectations, which can then affect leveraged positioning and spot demand. No quantified causal coefficient has been adopted. Existing monitors 44 and 45 will be retained, and a new review will be added at 12:30 UTC on the next run. Earnings and FDA company-specific events are not included unless a documented transmission emerges. Sources include the New York Fed, Federal Reserve, BLS, and Census Bureau websites, as well as the iShares website for IBIT and ETHA, and the Ethereum Magicians website.